Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14032325 | 1.00 | MEN1 (0.52) | MEN1KMT2AALDH1A1MAPTKDM4E | |
| SCHEMBL8430296 | 0.93 | MEN1 (0.47) | MEN1KMT2AALDH1A1MAPTKDM4E | |
| SCHEMBL8430294 | 0.93 | MEN1 (0.47) | MEN1KMT2AALDH1A1MAPTKDM4E | |
| SCHEMBL11720751 | 0.87 | ALDH1A1 (0.49) | MEN1KMT2AALDH1A1MAPTKDM4E | |
| SCHEMBL11720747 | 0.87 | ALDH1A1 (0.49) | MEN1KMT2AALDH1A1MAPTKDM4E | |
| SCHEMBL25669500 | 0.86 | MEN1 (0.58) | MEN1KMT2AALDH1A1MAPTKDM4E | |
| SCHEMBL8655219 | 0.85 | ALDH1A1 (0.52) | ALDH1A1MAPTKDM4ENPC1THRB | |
| SCHEMBL8657420 | 0.85 | MEN1 (0.46) | MEN1KMT2AALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL13906640 | 0.85 | MEN1 (0.46) | MEN1KMT2AALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL27569641 | 0.85 | HDAC3 (0.50) | MEN1KMT2AALDH1A1MAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183180-A1 | PROCESS OF MAKING ROXADUSTAT | SUZHOU PENGXU PHARMATECH CO., LTD. (CN) | 2023-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183180-A1 | PROCESS OF MAKING ROXADUSTAT | CYP2B6, UGT1A6, CYP2D6 | MEN1 2734/4885KMT2A 1095/4885ALDH1A1 752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.